| Literature DB >> 29872749 |
Rocco Adiutori1, Johan Aarum2, Irene Zubiri1, Michael Bremang3, Stephan Jung4, Denise Sheer2, Ian Pike3, Andrea Malaspina1.
Abstract
Protein aggregation in biofluids is a poorly understood phenomenon. Under normal physiological conditions, fluid-borne aggregates may contain plasma or cell proteins prone to aggregation. Recent observations suggest that neurofilaments (Nf), the building blocks of neurons and a biomarker of neurodegeneration, are included in high molecular weight complexes in circulation. The composition of these Nf-containing hetero-aggregates (NCH) may change in systemic or organ-specific pathologies, providing the basis to develop novel disease biomarkers. We have tested ultracentrifugation (UC) and a commercially available protein aggregate binder, Seprion PAD-Beads (SEP), for the enrichment of NCH from plasma of healthy individuals, and then characterised the Nf content of the aggregate fractions using gel electrophoresis and their proteome by mass spectrometry (MS). Western blot analysis of fractions obtained by UC showed that among Nf isoforms, neurofilament heavy chain (NfH) was found within SDS-stable high molecular weight aggregates. Shotgun proteomics of aggregates obtained with both extraction techniques identified mostly cell structural and to a lesser extent extra-cellular matrix proteins, while functional analysis revealed pathways involved in inflammatory response, phagosome and prion-like protein behaviour. UC aggregates were specifically enriched with proteins involved in endocrine, metabolic and cell-signalling regulation. We describe the proteome of neurofilament-containing aggregates isolated from healthy individuals biofluids using different extraction methods.Entities:
Keywords: Blood biomarkers; MS-based proteomics; NCH, neurofilament-containing hetero-aggregates; Neurofilaments; Nf, neurofilaments; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain; PPS, pooled plasma sample; Protein aggregates; SEP, Seprion PAD-beads; Seprion PAD-Beads; UC, ultracentrifugation; Ultracentrifugation
Year: 2018 PMID: 29872749 PMCID: PMC5986704 DOI: 10.1016/j.bbrep.2018.04.010
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Conditions for aggregate enrichment by Seprion Magnetic PAD-Beads: volumes of samples and reagents; CB: Capture Buffer; SR: Seprion-PAD Reagent.
| 800 | 400 | 400 | 400 | 400 | 400 | 200 | |
| 200 | 400 | 200 | 200 | 400 | 400 | 200 | |
| 0 | 0 | 200 | 200 | 0 | 0 | 400 | |
| 100 | 200 | 100 | 100 | 100 | 100 | 100 | |
| 100 | 200 | 200 | 100 | 200 | 100 | 100 | |
Fig. 1Western blot analysis of pooled plasma sample (PPS) using anti-neurofilament-High (NfH), anti-Medium (NfM) and anti-Low (NfL) antibodies after filtration with Amicon 100 filters (100 kDa molecular cut-off). Lanes contain in order from left to right: PPS subjected to pre-treatment with 0.5 M urea and Barb2EDTA buffer for 1 h at RT, PPS diluted 1:1 with Barb2EDTA Buffer for 1 h at RT and untreated PPS kept at + 4 °C. The blots show the three neurofilament proteins, with NfL appearing at approx. 30 kDa, NfM at 117 kDa and NfH at 238 kDa. No bands with molecular weight higher than the expected sizes, indicative of stable Nf-containing aggregates, were detected.
Fig. 2Comparison of aggregate fractions extracted from pooled plasma samples (PPS) using ultracentrifugation (UC) and Seprion extraction Pads (SEP). (A): Comassie-stained SDS-PAGE gel showing the different protein profiles of the enriched fractions extracted using the two methodologies. (B-C): western Blots analysis showing presence of Nf within the aggregates fractions obtained through UC (B) and SEP (C). Arrow highlights the presence of anti-NfH-containing high MW band.
Fig. 3UC and SEP aggregates fractions for LC-MS/MS analysis. (A) SDS-PAGE showing gel bands dissected for in-gel Trypsin digestion for LC-MS/MS (a total of 15 for both UC and SEP) (same picture shown in A); (B) Protein Identification performed with Proteome Discoverer 1.4 generated 369 and 605 proteins unique to UC and SEP respectively; 225 were shared by the two extraction methods (2 peptides for protein as minimum and a peptide count only in the top scored proteins were utilized). UC: ultracentrifugation; SEP: Seprion extraction pads.
MS analysis of enriched aggregates: main features of the protein groups identified using Proteome Discoverer 1.4. Data are shown for the protein groups identified by ultracentrifugation only (UC), by Seprion Pads only (SEP), or “shared” by the two enrichment methods. The shared fraction included only the protein isoforms in common and not the parental proteins: coverage values are normally distributed and the mean was used for comparison.
| UC | 215,993 | 35,779 | 16.56 | 371 | 31.2% | 5.0 | 6.0 | 12.0 |
| SEP | 210,875 | 34,865 | 16.53 | 609 | 25.6% | 5.0 | 6.0 | 8.0 |
| UC (shared) | 209 | 34.7% | 7.0 | 10.0 | 28.0 | |||
| SEP (shared) | 209 | 35.3% | 8.0 | 10.0 | 21.0 |
Fig. 4Bioinformatics analysis of the MS proteomics data of the aggregate extraction products obtained using Protein Analysis THrough Evolutionary Relationships (PANTHER). Pie charts representing Cellular Component (CC) category composition in (A) shared proteins between UC and SEP, (B) unique proteins detected by UC and (C) by SEP. In brackets, the number of proteins identified by PANTHER for each group.
Top 10 enriched KEGG pathways in the pool of UC and SEP shared proteins. PValue: p-value from hypergeometric test; FDR: False Discovery Rate from Bonferroni Hypothesis.
| hsa04610 | Complement and coagulation cascades - Homo sapiens (human) | 79 | 40 | 1.23 | 32.42 | 0.00E+00 | 0.00E+00 |
| hsa05150 | Staphylococcus aureus infection - Homo sapiens (human) | 56 | 13 | 0.87 | 14.86 | 1.72E−12 | 2.60E−10 |
| hsa05020 | Prion diseases - Homo sapiens (human) | 35 | 8 | 0.55 | 14.63 | 4.53E−08 | 4.58E−06 |
| hsa05133 | Pertussis - Homo sapiens (human) | 76 | 10 | 1.19 | 8.42 | 2.30E−07 | 1.74E−05 |
| hsa04510 | Focal adhesion - Homo sapiens (human) | 203 | 14 | 3.17 | 4.42 | 2.78E−06 | 1.69E−04 |
| hsa05322 | Systemic lupus erythematosus - Homo sapiens (human) | 135 | 11 | 2.11 | 5.22 | 7.20E−06 | 3.64E−04 |
| hsa05130 | Pathogenic Escherichia coli infection - Homo sapiens (human) | 55 | 7 | 0.86 | 8.15 | 2.04E−05 | 8.85E−04 |
| hsa04145 | Phagosome - Homo sapiens (human) | 154 | 11 | 2.41 | 4.57 | 2.52E−05 | 9.56E−04 |
| hsa04512 | ECM-receptor interaction - Homo sapiens (human) | 82 | 7 | 1.28 | 5.47 | 2.71E−04 | 9.13E−03 |
| hsa04611 | Platelet activation - Homo sapiens (human) | 122 | 8 | 1.91 | 4.20 | 6.03E−04 | 1.83E−02 |
Top 10 enriched KEGG pathways for UC_PPS. PValue: p-value from hypergeometric test; FDR: False Discovery Rate from Bonferroni Hypothesis.
| hsa00020 | Citrate cycle (TCA cycle) - Homo sapiens (human) | 30 | 3 | 0.13 | 23.26 | 2.69E−04 | 0.06 |
| hsa04512 | ECM-receptor interaction - Homo sapiens (human) | 82 | 4 | 0.35 | 11.35 | 3.85E−04 | 0.06 |
| hsa04145 | Phagosome - Homo sapiens (human) | 154 | 4 | 0.66 | 6.04 | 4.00E−03 | 0.40 |
| hsa01200 | Carbon metabolism - Homo sapiens (human) | 114 | 3 | 0.49 | 6.12 | 1.25E−02 | 0.95 |
| hsa05144 | Malaria - Homo sapiens (human) | 49 | 2 | 0.21 | 9.50 | 1.85E−02 | 1.00 |
| hsa05130 | Pathogenic Escherichia coli infection - Homo sapiens (human) | 55 | 2 | 0.24 | 8.46 | 2.30E−02 | 1.00 |
| hsa00310 | Lysine degradation - Homo sapiens (human) | 59 | 2 | 0.25 | 7.89 | 2.63E−02 | 1.00 |
| hsa04920 | Adipocytokine signalling pathway - Homo sapiens (human) | 70 | 2 | 0.30 | 6.65 | 3.60E−02 | 1.00 |
| hsa03320 | PPAR signalling pathway - Homo sapiens (human) | 72 | 2 | 0.31 | 6.46 | 3.79E−02 | 1.00 |
| hsa04918 | Thyroid hormone synthesis - Homo sapiens (human) | 74 | 2 | 0.32 | 6.29 | 3.99E−02 | 1.00 |
Top 10 enriched KEGG pathways for SEP_PPS. PValue: p-value from hypergeometric test; FDR: False Discovery Rate from Bonferroni Hypothesis.
| hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) | 216 | 27 | 5.23 | 5.16 | 1.11E−12 | 3.37E−10 |
| hsa04611 | Platelet activation - Homo sapiens (human) | 122 | 16 | 2.95 | 5.42 | 3.05E−08 | 3.67E−06 |
| hsa05131 | Shigellosis - Homo sapiens (human) | 65 | 12 | 1.57 | 7.62 | 3.64E−08 | 3.67E−06 |
| hsa04270 | Vascular smooth muscle contraction - Homo sapiens (human) | 121 | 15 | 2.93 | 5.12 | 1.80E−07 | 1.24E−05 |
| hsa04921 | Oxytocin signalling pathway - Homo sapiens (human) | 159 | 17 | 3.85 | 4.42 | 2.36E−07 | 1.24E−05 |
| hsa04144 | Endocytosis - Homo sapiens (human) | 260 | 22 | 6.30 | 3.49 | 2.46E−07 | 1.24E−05 |
| hsa05130 | Pathogenic Escherichia coli infection - Homo sapiens (human) | 55 | 10 | 1.33 | 7.51 | 6.07E−07 | 2.63E−05 |
| hsa04530 | Tight junction - Homo sapiens (human) | 139 | 14 | 3.37 | 4.16 | 5.87E−06 | 2.23E−04 |
| hsa04510 | Focal adhesion - Homo sapiens (human) | 203 | 17 | 4.92 | 3.46 | 7.27E−06 | 2.45E−04 |
| hsa04062 | Chemokine signalling pathway - Homo sapiens (human) | 187 | 16 | 4.53 | 3.53 | 1.04E−05 | 3.16E−04 |